FDA Requires Vision Loss Warning on GLP-1 Medication Labels

The U.S. FDA has updated regulations for GLP-1 medication manufacturers, mandating a new label warning about a potential, albeit very low, risk of vision loss. This regulatory action aims to ensure both patients and healthcare providers are fully informed regarding this possible adverse effect associated with the widely used drugs.